Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 50610-32-7 | MDL No. : | MFCD00221890 |
Formula : | C10H11ClN2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | WGHROLNIFFZEQJ-UHFFFAOYSA-N |
M.W : | 226.66 | Pubchem ID : | 4608864 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.2 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 60.08 |
TPSA : | 58.2 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.16 cm/s |
Log Po/w (iLOGP) : | 1.93 |
Log Po/w (XLOGP3) : | 0.74 |
Log Po/w (WLOGP) : | 1.88 |
Log Po/w (MLOGP) : | 1.56 |
Log Po/w (SILICOS-IT) : | 1.64 |
Consensus Log Po/w : | 1.55 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.74 |
Solubility : | 4.09 mg/ml ; 0.0181 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.54 |
Solubility : | 6.52 mg/ml ; 0.0288 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -3.8 |
Solubility : | 0.0363 mg/ml ; 0.00016 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.5 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P273-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335-H412 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
[ 15308-01-7 ]
2-Chloro-N-(2,6-dichlorophenyl)-N-phenylacetamide
Similarity: 0.86
[ 13167-25-4 ]
1-(2,4,6-Trichlorophenyl)-1H-pyrrole-2,5-dione
Similarity: 0.83
[ 7160-22-7 ]
N-(3,4-Dichlorophenyl)pivalamide
Similarity: 0.79
[ 183500-94-9 ]
1-(3-Chlorophenyl)piperazin-2-one hydrochloride
Similarity: 0.79
[ 15308-01-7 ]
2-Chloro-N-(2,6-dichlorophenyl)-N-phenylacetamide
Similarity: 0.86
[ 13167-25-4 ]
1-(2,4,6-Trichlorophenyl)-1H-pyrrole-2,5-dione
Similarity: 0.83
[ 7160-22-7 ]
N-(3,4-Dichlorophenyl)pivalamide
Similarity: 0.79
[ 183500-94-9 ]
1-(3-Chlorophenyl)piperazin-2-one hydrochloride
Similarity: 0.79
[ 15308-01-7 ]
2-Chloro-N-(2,6-dichlorophenyl)-N-phenylacetamide
Similarity: 0.86
[ 13167-25-4 ]
1-(2,4,6-Trichlorophenyl)-1H-pyrrole-2,5-dione
Similarity: 0.83
[ 7160-22-7 ]
N-(3,4-Dichlorophenyl)pivalamide
Similarity: 0.79
[ 183500-94-9 ]
1-(3-Chlorophenyl)piperazin-2-one hydrochloride
Similarity: 0.79
[ 3460-23-9 ]
N-(4-Bromo-2-chlorophenyl)acetamide
Similarity: 0.79
[ 15308-01-7 ]
2-Chloro-N-(2,6-dichlorophenyl)-N-phenylacetamide
Similarity: 0.86
[ 7160-22-7 ]
N-(3,4-Dichlorophenyl)pivalamide
Similarity: 0.79
[ 3460-23-9 ]
N-(4-Bromo-2-chlorophenyl)acetamide
Similarity: 0.79